New Proteins in Body Fluids as Potential Biomarker for Alzheimer's Disease: a Pilot Study
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Alzheimer Disease, Late Onset
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
- Enrollment
- 20
- Locations
- 1
- Primary Endpoint
- Differences in blood, saliva and urine protein levels in patients with Alzheimer's Disease versus healthy controls.
- Last Updated
- 12 years ago
Overview
Brief Summary
Alzheimer's disease (AD) is the most common neurodegenerative disorder afflicting the elderly. Currently, some biochemical tests performed on Cerebrospinal Fluid (CSF) samples have demonstrated to discriminate to some extend between AD and non-AD individuals based on the levels of tau, phospho-tau or Aβ42. We aim to investigate newly identified proteins whose levels increase during the Braak Stages of AD that are accessible in other body fluids such as blood, urine or saliva. The detection of these proteins would allow performing simple tests in case its levels were confirmed to be associated with the AD pathology.
Detailed Description
We do not desire to provide a more extensive description
Investigators
Prof Dr Jos Tournoy
MD PhD
Universitaire Ziekenhuizen KU Leuven
Eligibility Criteria
Inclusion Criteria
- •mild to moderate AD
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Differences in blood, saliva and urine protein levels in patients with Alzheimer's Disease versus healthy controls.
Time Frame: Up to 1 year
Protein levels will be measured by classical immunoblotting blot analysis and quantified; Classical statistical analyses will be performed in order to detect any significant differences.